The earnings call reflected a balanced outlook with significant achievements such as record new customer starts and international growth offset by challenges in the U.S. market, particularly in revenue and DME channel dynamics. The launch of Stelo and a strategic focus on the 15-day sensor submission demonstrate proactive steps towards future growth.

Company Guidance

In the third quarter of 2024, Dexcom reported worldwide revenue of $994 million, marking a 2% increase on a reported basis and a 3% increase on an organic basis from the previous year. The U.S. revenue saw a decline of 2% to $702 million, primarily due to slower new customer starts and a shift in channel dynamics, along with nearly 100% rebate eligibility impacting growth by approximately 6 percentage points. However, international revenue grew by 12%, reaching $292 million, supported by the accelerated availability of G7 and Dexcom ONE+ product platforms. The company maintained its 2024 guidance of $4.00 billion to $4.05 billion, indicating an organic growth of 11% to 13% for the year, with expectations for a continued ramp in U.S. sales force productivity and a strategic focus on stabilizing channel dynamics. Adjusted EBITDA for the quarter was $300.1 million, accounting for 30.2% of the revenue. Looking forward, Dexcom emphasized its pathway to higher growth, confident in achieving the $4.6 billion revenue target and associated margin goals for 2025, leveraging the launch of the Stelo product, strategic international market expansions, and the anticipated launch of the 15-day G7 sensor currently under review by the FDA.

Record New Customer Starts

The company reported new customer starts returning to record levels in Q3, highlighting growth in the U.S. prescriber base by nearly 35,000 clinicians.

International Revenue Growth

International revenue grew by 12% to $292 million, with organic revenue growth reaching 16% for the quarter, driven by the expanded availability of G7 and Dexcom ONE+.

Launch of Stelo Product

The launch of Stelo in the U.S. represents a significant milestone, with early adopters providing positive feedback and 50% of customers signing up for a subscription model.

15-Day G7 Sensor Submission

Dexcom submitted the 15-day G7 sensor to the FDA, marking a step forward in enhancing customer experience and potential cost efficiencies.

Share Repurchase Program

The company executed a $750 million share repurchase program, highlighting financial flexibility and confidence in future performance.

---

Dexcom (DXCM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DXCM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 06, 2025	2024 (Q4)	0.52 / -	0.5	―	―	―
Oct 24, 2024	2024 (Q3)	0.43 / 0.45	0.5	-10.00% (-0.05)
Jul 25, 2024	2024 (Q2)	0.39 / 0.43	0.34	26.47% (+0.09)
Apr 25, 2024	2024 (Q1)	0.27 / 0.32	0.17	88.24% (+0.15)
Feb 08, 2024	2023 (Q4)	0.43 / 0.50	0.34	47.06% (+0.16)
Oct 26, 2023	2023 (Q3)	0.34 / 0.50	0.28	78.57% (+0.22)
Jul 27, 2023	2023 (Q2)	0.23 / 0.34	0.17	100.00% (+0.17)
Apr 27, 2023	2023 (Q1)	0.15 / 0.17	0.08	112.50% (+0.09)
Feb 09, 2023	2022 (Q4)	0.27 / 0.34	0.17	100.00% (+0.17)
Oct 27, 2022	2022 (Q3)	0.24 / 0.28	0.222	26.13% (+0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DXCM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 24, 2024	$74.85	$73.44	-1.88%
Jul 25, 2024	$107.85	$64.00	-40.66%
Apr 25, 2024	$138.01	$124.34	-9.91%
Feb 08, 2024	$127.05	$120.47	-5.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---